Detalhe da pesquisa
1.
[68Ga]Ga-Pentixafor for PET Imaging of Vascular Expression of CXCR-4 as a Marker of Arterial Inflammation in HIV-Infected Patients: A Comparison with 18F[FDG] PET Imaging.
Biomolecules;
10(12)2020 12 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33287237
2.
Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study.
Clin Endocrinol (Oxf);
70(5): 757-68, 2009 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19178516
3.
Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.
J Nucl Med;
59(6): 915-921, 2018 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29191855
4.
Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study.
J Nucl Med;
59(6): 909-914, 2018 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29025985
5.
Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect.
J Nucl Med;
58(9): 1435-1441, 2017 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28450554
6.
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Semin Nucl Med;
36(2): 147-56, 2006 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16517236
7.
(177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model.
EJNMMI Res;
6(1): 50, 2016 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27294582
8.
Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles.
J Clin Pharmacol;
45(7): 836-44, 2005 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15951474
9.
Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors.
J Nucl Med;
44(10): 1556-60, 2003 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-14530466
10.
Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases.
Cancer Biother Radiopharm;
18(4): 581-8, 2003 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-14503953
11.
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Cancer Biother Radiopharm;
19(1): 35-41, 2004 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15068609
12.
90Y-edotreotide for metastatic carcinoid refractory to octreotide.
J Clin Oncol;
28(10): 1652-9, 2010 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20194865
13.
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.
Clin Endocrinol (Oxf);
66(6): 859-68, 2007 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17465997
14.
Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues.
Nephrol Dial Transplant;
19(9): 2275-81, 2004 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15252161
15.
86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.
Eur J Nucl Med Mol Imaging;
30(4): 510-8, 2003 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12582815
16.
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Eur J Nucl Med Mol Imaging;
31(10): 1386-92, 2004 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15175836